menu search
Trades24h logo
 Register
close Tap here to search
  1. Home

  2. News

  3. Stock Details

Subscribe To  

  Price Alert   Latest News   Economic Calendar News

APTX / Aptinyx's stock falls 48% after drug fails in Phase 2b trial

Aptinyx's stock falls 48% after drug fails in Phase 2b trial
Shares of Aptinyx Inc. APTX, -4.49% tumbled 48.7% in premarket trading on Thursday after the company said an experimental treatment for painful diabetic peripheral neuropathy failed to meet the primary endpoint in a Phase 2b clinical trial. "The data from this study do not currently point to a path forward in development for painful DPN," Aptinyx CEO Andy Kidd said in a news release. Read More
Hmarkets Logo
Demo chevron_right Live Account chevron_right See Partner Details

Content Topics

Aptinyx

Stock

Falls

After

Drug

Fails

Phase

Trial

Aptinyx s

APTX

Posted: Apr 7 2022, 08:44
Author Name: Market Watch
Views: 102562

APTX News  

Here's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock Now

By Zacks Investment Research
March 30, 2023

Here's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock Now

After losing some value lately, a hammer chart pattern has been formed for Aptinyx Inc. (APTX), indicating that the stock has found support. This, com more_horizontal

Aptinyx to Present at the SVB Securities Global Biopharma Conference

By Business Wire
January 31, 2023

Aptinyx to Present at the SVB Securities Global Biopharma Conference

EVANSTON, Ill.--( BUSINESS WIRE )--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the more_horizontal

Aptinyx Inc. (APTX) CEO Andy Kidd on Q3 2022 Results - Earnings Call Transcript

By Seeking Alpha
November 8, 2022

Aptinyx Inc. (APTX) CEO Andy Kidd on Q3 2022 Results - Earnings Call Transcript

Aptinyx Inc. (NASDAQ:APTX ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Patrick Flavin - Senior Manager, Corpora more_horizontal

Aptinyx Inc. (APTX) CEO Andy Kidd on Q2 2022 Results - Earnings Call Transcript

By Seeking Alpha
August 7, 2022

Aptinyx Inc. (APTX) CEO Andy Kidd on Q2 2022 Results - Earnings Call Transcript

Aptinyx Inc. (NASDAQ:APTX ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Patrick Flavin - Senior Manager, Corporate more_horizontal

Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022

By Business Wire
July 15, 2022

Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the t more_horizontal

Aptinyx to Participate in H.C. Wainwright Global Investment Conference

By Business Wire
May 18, 2022

Aptinyx to Participate in H.C. Wainwright Global Investment Conference

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the t more_horizontal

Aptinyx to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

By Business Wire
April 27, 2022

Aptinyx to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the t more_horizontal

Aptinyx (APTX) Tanks as Neuropathic Pain Study Misses Goal

By Zacks Investment Research
April 8, 2022

Aptinyx (APTX) Tanks as Neuropathic Pain Study Misses Goal

Aptinyx's (APTX) phase IIb study evaluating the effects of NYX-2925 in patients with painful diabetic peripheral neuropathy misses the primary endpoin more_horizontal

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

©2014-2024 All Rights Reserved. I.C

Hand-crafted & made with Love

logo close

Search within

Pages Search Results: